Mesoblast Limited (ASX:MSB) Featured Prominently At International Scientific Conferences

Melbourne, Sep 20, 2010 AEST (ABN Newswire) - Clinical advances by regenerative medicine company Mesoblast Limited (ASX:MSB) (PINK:MBLTY) were featured prominently at the 39th annual meeting of the International Society for Experimental Hematology (ISEH) and the Tissue Engineering and Regenerative Medicine International Society (TERMIS) Asia Pacific meeting, both held over the past several days.

More than 500 international participants attended the ISEH and TERMIS conferences which promoted scientific knowledge and clinical application of stem cell research, basic haematology, immunology, cell and gene therapy, tissue engineering and regenerative medicine.

Mesoblast's scientists and clinicians were highlighted at plenary sessions and special symposia, which featured the Company's clinical programs, including those for congestive heart failure, degenerative spinal disease, and bone marrow transplantation. International delegates were told that the clinical results indicate that Mesoblast's technology has the potential to improve both quality of life and survival outcomes in life-threatening diseases.

Mesoblast will continue to ensure that its clinical achievements and cutting edge research are highlighted and recognised at respected and prestigious conferences, meetings attended by key opinion leaders, and peer-reviewed publications.

Contact

Julie Meldrum Corporate Communications Director Mesoblast Limited Tel: +61-3-9639-6036 Mob: +61-419-228-128 Email: julie.meldrum@mesoblast.com http://www.mesoblast.com